Moreover, FGFR1 and/or FGF3 gene amplification is associated with resistance to HER2 targeted therapy, a shorter PFS survival and a lower pathological complete response (CR) in HER2 (+) early breast cancer treated with neoadjuvant anti‐HER2 therapy.42 Here, FGFR1 is linked to breast cancer.